Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.
about
Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemiaAntifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.Aspergillus fumigatus and aspergillosisHistory of medical mycology in the united states.Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.Aspergillus infections in transplant recipients.Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis.Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosisHost biomarkers of invasive pulmonary aspergillosis to monitor therapeutic responseCurrent status of nonculture methods for diagnosis of invasive fungal infectionsAutopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis.Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat modelDistribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma samplingSafety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Role of NADPH oxidase versus neutrophil proteases in antimicrobial host defense.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.Approaches to fungal diagnosis in transplantation.Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?Antifungal agents: chemotherapeutic targets and immunologic strategies.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelCharacterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis.Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis.Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.Carrier effects on biological activity of amphotericin B.Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis.Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.Liposomal amphotericin B: clinical experience and perspectives.
P2860
Q26824260-E0E26965-8D39-4041-8A9C-22D1550F75A5Q28349552-7443ECD0-89A9-4C13-9C2E-C0C688652B02Q28369150-F9842FBA-4809-49CB-92B5-3F15B2FB77FEQ29617908-145A3AD5-F0B1-4D20-B10A-0A1409D8E76DQ30452877-DAB5EFC8-960E-4476-A495-FEE3DA565B17Q33689514-8276FD95-7FCB-45E5-B79C-D58B8EDF9388Q33697079-1071697B-C8B8-4F97-A9AC-D31C1CD2F31AQ33719294-53EA8F33-EDE0-4C4A-8833-C33A8EB33B56Q33721998-049F3728-512F-47F4-871A-3676040A9117Q33769712-940E21B4-6BB4-4131-B074-CD66FFE89FBEQ33798161-337165AE-A4BB-4C79-B2C8-FDE96481FC21Q33906498-E40C3E37-C9CC-49ED-8BE9-A07DFFE246BAQ33962952-06E6514C-9FB4-4F57-944C-11A8A17050AEQ33966364-24D983D1-64DF-473F-BE35-93A60419BDE9Q33978764-F49C7B60-AC6E-4A99-818D-BF3E63E9F678Q33978902-A2CDA23F-BE60-46C5-BD7F-86B1BA8171DEQ33983159-DA6FF12A-06B7-4210-BB62-FB8FF7F6CE1FQ33983629-B2ECC0E9-142C-44E2-8C65-31C3BEF314E2Q34098141-CFE24222-645B-4525-B24A-A06FA52A83BCQ34104748-5F3D1025-EBA8-4004-9BC2-5C8BE995A82DQ34108880-47FFD178-9331-43B0-BEF7-3ABE927EA263Q34195380-566FDA28-8867-416C-8704-B8765D3CFAF6Q34251910-49047309-1461-410E-92C2-3553653AF74FQ34290097-3BED69BE-DC57-41A8-947F-D194C5CF993EQ34294880-00DCC87F-3B4C-4ED8-A45F-300AE8AB5E25Q34294904-D3F686F7-8537-41EB-ACFB-B4DC824C9324Q34400044-C4E694A0-D757-482B-BF82-B2AC3A6B57A0Q34455633-5B870C75-AB53-4190-9AC4-F220160785E1Q34510443-12821154-D80A-4824-97D5-AD33038FEC89Q34680675-9C7D8D8E-E3EA-4423-A1C5-AB0E0B6D5F7BQ34719835-95F0D44E-926F-4AAA-BE8B-BF20CE7CE8D1Q34952419-61EB37ED-BDCA-4BCA-83D1-72DA1A37BC2EQ35091593-B1C08E1E-034D-4B72-A339-6CBB27C2F9EBQ35114249-036DF5F4-5A3F-4B94-AF08-D8B26C3B1EAFQ35118084-410648FC-9F84-434A-838F-515684D62254Q35372581-958F1C07-D15D-43ED-AF79-421FB38D5113Q35385786-EE91865F-251E-4331-A79E-385F0C093EB1Q35598975-D3A9BCE4-D85D-4E5C-B5FF-1F15C6E868F9Q35647688-D2DFFF2E-116E-4157-9C95-8D3746C83D55Q36140647-AD740916-D7A1-4422-A00D-BADB90D179EC
P2860
Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Efficacy of unilamellar liposo ...... annan as markers of infection.
@en
Efficacy of unilamellar liposo ...... annan as markers of infection.
@nl
type
label
Efficacy of unilamellar liposo ...... annan as markers of infection.
@en
Efficacy of unilamellar liposo ...... annan as markers of infection.
@nl
prefLabel
Efficacy of unilamellar liposo ...... annan as markers of infection.
@en
Efficacy of unilamellar liposo ...... annan as markers of infection.
@nl
P2093
P356
P1476
Efficacy of unilamellar liposo ...... mannan as markers of infection
@en
P2093
A Francesconi
J Shelhamer
P304
P356
10.1093/INFDIS/169.2.356
P407
P50
P577
1994-02-01T00:00:00Z